Treatment for mixed cognitive impairments and emotional disorders in young and middle-aged patients
| Autor: | A. B. Lokshina, L. M. Antonenko, E. Yu. Solovyeva, T. Gorskaya, V. A. Parfenov |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Secondary education Health improvement mood 030204 cardiovascular system & hematology memory 03 medical and health sciences 0302 clinical medicine medicine tanakan health RC346-429 activity attention Psychiatry and Mental health Clinical Psychology Safety profile Mood efficiency Test score emotional disorders Physical therapy Observational study Neurology. Diseases of the nervous system Neurology (clinical) cognitive impairments Psychology 030217 neurology & neurosurgery |
| Zdroj: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 8, Iss 2, Pp 17-23 (2016) |
| ISSN: | 2310-1342 2074-2711 |
| Popis: | Objective: to evaluate the efficacy of Tanakan® (EGB761®) used in young and middle-aged patients with mixed cognitive impairments (CI) and emotional diseases. Patients and methods. An open-label observational study of the efficacy of Tanakan® was conducted in 54 patients aged 18–4 years with CI and psychoemotional disorders. Tanakan® was administered at a daily dose of 120 mg (40 mg t.i.d) for 3 months. Results. Tanakan® therapy resulted in health improvement, as shown by the HAM (Health, Activity, Mood) questionnaire; the mean score of the latter increased from 3.86 at baseline to 4.84 after 3 months of treatment. There were improvements in three HAM questionnaire items: the mean score of the item «Health» increased from 3.69 to 4.79; that of the item «Activity» from 3.65 to 4.58, and that the item «Mood» from 4.25 to 5.14 after the completion of the investigation. Tanakan® therapy also demonstrated improvements in memory (the mean number of correctly repeated words increased from 5.7 to 6.7 at the beginning of a visit and from 4.2 to 5.8 at its end) and in attention (the mean symbol-digit coding test score increased from 48.1 to 55.7%. There were no clinically relevant differences between patients with higher and secondary education in the efficacy of Tanakan®. Conclusion. Tanakan® had a very good safety profile; no adverse drug events were recorded during the investigation. Almost all the 53 (98.1%) of the 54 patients were satisfied with Tanakan® therapy results after 3 months of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|